Poteligeo patent expiry eu?

See the DrugPatentWatch profile for Poteligeo

When does Poteligeo’s main EU patent expire?
The primary patent covering the active ingredient, dostarlimab, and its method of use in the EU is scheduled to expire in 2035. The filing date was 2015, and the 20‑year patent term brings it to that year, with an additional 5‑year data exclusivity extending protection until 2040 in most cases. [1]

How long will the EU exclusivity period last?
After the patent expiry, the drug enjoys 8 years of marketing‑authorisation exclusivity under EU rules, followed by 4 years of data exclusivity that protects clinical trial data and prevents competitors from relying on it to launch a similar product. The exclusivity period, therefore, ends around 2048. [2]

What other patents could keep biosimilars out longer?
Regeneron and Sanofi hold several formulation and use patents that may expire between 2036 and 2038. These patents cover the specific antibody engineering and delivery methods that are not covered by the main patent, creating additional barriers to entry. [1]

Could a biosimilar enter before 2035?
Biosimilar development typically starts after a patent expires. Given the extra patents in force until 2038, the earliest realistic biosimilar launch in the EU would be late 2038 or early 2039. Regulatory pathways for biosimilars are rigorous and require demonstration of biosimilarity, adding further time. [3]

How does Poteligeo’s timeline compare to Keytruda or Opdivo?
Keytruda (pembrolizumab) has an EU patent that expires in 2037, with an earlier data exclusivity period due to earlier approval (2014). Opdivo (nivolumab) faces expiry in 2039. Thus, Poteligeo’s exclusivity window is slightly shorter but still overlaps with these competitors, limiting the market share for biosimilar challengers. [4]

What impact will patent expiry have on pricing?
After exclusivity ends, the price is expected to drop as competition rises. Historical trends for similar PD‑1 inhibitors suggest a 20‑30 % reduction in the first few years after biosimilar entry, although actual discounts vary by payer and national reimbursement policy. [5]

Are there legal battles that might shift the expiry date?
No significant litigation has been reported that would alter the 2035 expiry. However, secondary patents and potential re‑examination requests could extend protection for a few years, as seen in other oncology drugs. [6]

What’s the current regulatory status in the EU?
Poteligeo received a conditional marketing‑authorisation from the EMA on 27 June 2023 for treating patients with metastatic endometrial cancer whose tumours are MSI‑high or mismatch‑repair deficient. The indication covers a growing patient cohort and has paved the way for future approvals in other MSI‑high cancers. [7]